Reboxetine: A review of its use in depression

CNS Drugs

Volumn 12, Issue 1, 1999, Pages 65-83

  Holm, Kristin J ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Depression; Drug interactions; Pharmacodynamics; Pharmacokinetics; Reboxetine; Therapeutic use

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

COGNITION; DEPRESSION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; REVIEW;

EID: 0032806498     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912010-00006     Document Type: Review

References (45)

1. Riva M, Brunello N, Rovescalli AC, et al. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J Drug Dev 1989; 1 (4): 243-53
2. Dostert P, Benedetti MS, Poggesi J. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor [discussion S71-3]. Eur Neuropsychopharmacol 1997 Apr; 7 Suppl. 1: S23-35
3. Szabadi E, Bradshaw CM, Boston PF, et al. The human pharmacology of reboxetine. Hum Psychopharm 1998 Feb; 13 Suppl. 1: S3-12
4. Theofilopoulos N, McDade G, Szabadi E, et al. Effects of reboxetine and desipramine on the kinetics of the pupillary light reflex. Br J Clin Pharmacol 1995 Mar; 39: 251-5
5. Wong EHF, Graveel CR, Kagey ML, et al. Pharmacological selectivity of reboxetine: a selective noradrenaline reuptake inhibitor [abstract]. Eur Arch Psychiatry Clin Neurosci 1998 Sep; 248 Suppl. 2: S97
6. Schwaninger M, Weisbrod M, Knepel W. Progress in defining the mechanism of action of antidepressants: across receptors and into gene transcription. CNS Drugs 1997 Sep; 8: 237-43
7. Leonard BE. Mechanisms of action of antidepressants. CNS Drugs 1995; 4 Suppl. 1: 1-12
8. Leonard BE. Noradrenaline in basic models of depression. Eur Neuropsychopharmacol 1997 Apr; 7 Suppl. 1: S11-16
9. Dostert P, Castelli MG, Cicioni P, et al. Reboxetine prevents the tranylcypromine-induced increase in tyramine levels in rat heart. J Neural Transm 1994 Suppl. 41: 149-53
10. Kerr JS, Powell J, Hindmarch I. The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance. Br J Clin Pharmacol 1996 Aug; 42: 239-41
11. Herrmann WM, Fuder H. Reboxetine, a selective noradrenaline reuptake inhibitor, is non-sedative and does not impair psychomotor performance in healthy subjects. Hum Psychopharm 1998 Aug; 13: 425-33
12. Edwards DMF, Pellizzoni C, Breuel HP, et al. Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 1995 Aug; 16: 443-60
13. Jannuzzo MG, Strolin Benedetti M, Duchene P. Pharmacokinetics of reboxetine in the elderly [abstract]. 2nd Int Symp Meas Kinet In Vivo Drug Eff 1994: 94-6
14. Fiorentini F, Poggesi I, Jannuzzo MG, et al. Pharmacokinetics of reboxetine, a new selective noradrenaline uptake inhibitor, in patients with various degrees of hepatic and renal insufficiency [abstract]. Pharmacol Res 1997; 35 (3): 239
15. Strolin Benedetti M, Pellizzoni C, Poggest I, et al. Pharmacokinetics of reboxetine enantiomers in healthy volunteers [abstract]. Can J Physiol Pharmacol 1994; 72 Suppl. 1: 441.
16. Fleishaker JC, Mucci M, Pellizzoni C, et al. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics. Biopharm Drug Dispos 1999; 20: 53-7
17. Pellizzoni C, Strolin BM, Poggesi I, et al. Pharmacokinetics of reboxetine in healthy volunteers: relative bioavailability and food effect [abstract]. Pharmacol Res 1995; 31 Suppl.: 41
18. Pellizzoni C, Poggesi I, Jorgensen NP, et al. Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. Biopharm Drug Dispos 1996 Oct; 17: 623-33
19. Cocchiara G, Battagha R, Pevarello P, et al. Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur J Drug Metab Pharmacokinet 1991; 16 (3): 231-9
20. Pharmacia & Upjohn. Core data sheet: reboxetine. (Data on file)
21. Rocchetti M, Pellizzoni C, Poggesi I, et al. Genetic polymorphism and reboxetine metabolism [abstract]. Therapie 1995: 50 Suppl.: 80
22. Jannuzzo MG, Ryde M, Karlmark B, et al. Pharmacokinetics of reboxetine in healthy volunteers of different ages [abstract; special issue]. Eur Neuropsychopharmacol 1995 Sep; 5: 300
23. Jannuzzo MG, Bosc M, Renoux A, et al. Effect of reboxetine on the pharmacokinetics of lorazepam in healthy volunteers [abstract: special issue]. Eur Neuropsychopharmacol 1995 Sep; 5: 300-1
24. Fiorentini F, Poggesi I, Jannuzzo MG, et al. Effect of lorazepam on the pharmacokinetics of reboxetine in healthy volunteers [abstract; special issue]. Eur Neuropsychopharmacol 1995 Sep; 5: 300
25. Pharmacia & Upjohn. Edronax™. In: ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1988-99. London: Datapharm Publications Limited, 1998: 997-8
26. Montgomery SA, Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997; 11 (4 Suppl.): 9-15
27. Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998; 59 Suppl. 14: 4-7
28. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J Clin Psychiatry 1998; 59 Suppl. 14: 8-10
29. Ban TA, Gaszner P, Aguglia E, et al. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum Psychopharm 1998 Feb; 13 Suppl. 1: S29-39
30. Berzewski H, Van-Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes [discussion S71-3]. Eur Neuropsychopharmacol 1997 Apr; 7 Suppl. 1: S37-47
31. Massana J, Möller H-J, Burrows GD, et al. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999; 14 (2): 73-80
32. Dubini A, Bose M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 1997 Apr; 7 Suppl. 1: S49-55
33. Bose M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale [discussion S71-3]. Eur Neuropsychopharmacol 1997 Apr; 7 Suppl. 1: S57-70
34. Versiani M. Reboxetine is effective in preventing relapse and recurrence in major depressive disorder [poster]. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington, DC
35. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997; 11 (4 Suppl.): 33-7
36. Sambunaris A, Keppel HJ, Pinder R, et al. Development of new antidepressants. J Clin Psychiatry 1997; 58 Suppl. 6: 40-53
37. Hirschfeld RMA, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997 Jan 22 29; 277: 333-40
38. Henry JA, Rivas CA. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part I: depression and its treatment. Pharmacoeconomics 1997 May; 11: 419-43
39. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998; 59 Suppl. 14: 11-4
40. DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry 1998; 59 Suppl. 20: 85-93
41. Leonard BE. The role of noradrenaline in depression: A review. J Psychopharmacol 1997; 11 (4 Suppl.): S39-47
42. Schatzberg AF. Noradrenergic versus serotonergic antidepressants: predictors of treatment response. J Clin Psychiatry 1998; 59 Suppl. 14: 15-8
43. Weissman MM. Beyond symptoms: Social functioning and the new antidepressants. J Psychopharmacol 1997; 11 (4 Suppl.): S5-8
44. Norman TR, Leonard BE. Fast-acting antidepressants: can the need be met? CNS Drugs 1994 Aug; 2: 120-31
45. Caccia S. Metabolism of the newer antidepressants: an overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998 Apr; 34: 281-302